Health News
The vaccine was originally approved in 2024 for adults aged 60 and older.
Save
The Moderna campus in Norwood, Mass. on Dec. 2, 2020. Joseph Prezioso/AFP via Getty Images
By Zachary Stieber, Senior Reporter
Updated:
0:00
Federal regulators approved Moderna’s vaccine against Respiratory Syncytial Virus (RSV) for some adults as young as 18, the company said on June 12.
The Food and Drug Administration (FDA) expanded approval of the shot to people aged 18 to 59 who face an increased risk from RSV, a virus that typically causes cold-like symptoms, Moderna said in a statement.
